Equities

Ocular Therapeutix Inc

Ocular Therapeutix Inc

Actions
  • Price (EUR)9.64
  • Today's Change-0.439 / -4.36%
  • Shares traded170.00
  • 1 Year change+386.67%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 16:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments196102164
Total Receivables, Net262121
Total Inventory2.311.971.25
Prepaid expenses7.794.034.75
Other current assets, total0.15----
Total current assets232130191
Property, plant & equipment, net181812
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets252149205
LIABILITIES
Accounts payable4.395.124.59
Accrued expenses302622
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0
Other current liabilities, total0.260.58--
Total current liabilities353126
Total long term debt755451
Total debt755451
Deferred income tax------
Minority interest------
Other liabilities, total512939
Total liabilities161114117
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital789652634
Retained earnings (accumulated deficit)(698)(617)(546)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity913588
Total liabilities & shareholders' equity252149205
Total common shares outstanding1157777
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.